Cargando…

Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group

PURPOSE: Highly sensitized patients with a high level of panel reactive antibody (PRA) experience more episodes of antibody-mediated rejection (AMR) and poorer graft survival than non-sensitized patients. Rituximab is a well-known monoclonal anti-CD20 antibody that causes the depletion of B lymphocy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Young Hae, Huh, Kyu Ha, Kim, Yu Seun, Lee, Hyung Soon, Kim, Myoung Soo, Kim, Soo Jin, Kim, Hyun Jung, Kim, Soon Il, Joo, Dong Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Surgical Society 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373982/ https://www.ncbi.nlm.nih.gov/pubmed/22708094 http://dx.doi.org/10.4174/jkss.2012.82.6.335

Ejemplares similares

Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients
por: Park, Hoon Suk, et al.
Publicado: (2014)

Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2018)

Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: a propensity-matched study
por: Kim, Deok Gie, et al.
Publicado: (2019)

The impact of pretransplant 25-hydroxy vitamin D deficiency on subsequent graft function: An observational study
por: Kim, Hyunwook, et al.
Publicado: (2012)

Clinical significance of donor-specific anti-HLA-DR51/52/53 antibodies for antibody-mediated rejection in kidney transplant recipients
por: Park, Borae Geum, et al.
Publicado: (2019)

Risk factors for Pneumocystis jirovecii pneumonia (PJP) in kidney transplantation recipients
por: Lee, Su Hwan, et al.
Publicado: (2017)

Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study
por: Kim, Deok Gie, et al.
Publicado: (2019)

Changing pattern and safety of pretransplant malignancy in kidney transplant recipients
por: Ban, Tae Hyun, et al.
Publicado: (2019)

Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients
por: Kim, Hyung Woo, et al.
Publicado: (2023)

Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk
por: Kim, Eun Jin, et al.
Publicado: (2021)

The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
por: An, Gun Hee, et al.
Publicado: (2014)

Long-term compensation of renal function after donor nephrectomy
por: Lee, Yong Pyo, et al.
Publicado: (2020)

Clinical Characteristics and Treatment Outcomes of Colorectal Cancer in Renal Transplant Recipients in Korea
por: Kim, Jeong Yeon, et al.
Publicado: (2011)

The feasibility of organ transplantation during the COVID-19 outbreak: experiences from South Korea
por: Lee, Juhan, et al.
Publicado: (2020)

Clinical impact of serum bilirubin levels on kidney transplant outcomes
por: Lee, Juhan, et al.
Publicado: (2021)

Early hospital readmissions after ABO- or HLA- incompatible living donor kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2019)

Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome
por: Kim, Ji Hyun, et al.
Publicado: (2017)

Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation: A network meta-analysis
por: Lee, Hee Ryong, et al.
Publicado: (2021)

Graft-versus-host disease after simultaneous pancreas-kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2020)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Clinical impact and a prognostic marker of early rituximab treatment after rituximab reimbursement in Korean pemphigus patients
por: Song, Ahreum, et al.
Publicado: (2022)

Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
por: Kim, Young Hoon, et al.
Publicado: (2020)

2079. The Relation Between Panel Reactive Antibody Assay and Cytomegalovirus Reactivation in Seropositive Solid Organ Transplantation Recipients
por: Kwon, Da Eun, et al.
Publicado: (2018)

Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea
por: Ahn, Yo Han, et al.
Publicado: (2018)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Case Report: The Use of Rituximab in Antibody-Negative Autoimmune Encephalitis
por: Park, Soo-Hyun, et al.
Publicado: (2021)

Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product
por: Lee, Kyoung Hoon, et al.
Publicado: (2018)

Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
por: Go, Se‐Il, et al.
Publicado: (2016)

High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients
por: Kim, Jong Man, et al.
Publicado: (2014)

Invasive fungal infection in liver transplant recipients in a prophylactic era: A multicenter retrospective cohort study in Korea
por: Kim, Youn Jeong, et al.
Publicado: (2019)

Successful Treatment of a Korean Infant with Giant Cell Hepatitis with Autoimmune Hemolytic Anemia Using Rituximab
por: Kim, Young Ho, et al.
Publicado: (2020)

Pretransplant C-reactive protein-to-albumin ratio predicts mortality in kidney transplant recipients: a retrospective cohort study
por: Kwon, Jae Wan, et al.
Publicado: (2023)

Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin
por: Ban, Tae Hyun, et al.
Publicado: (2021)

Hepatitis B reactivation in patients with pemphigus vulgaris after immunosuppressive therapy including rituximab
por: Yoo, Dae San, et al.
Publicado: (2020)

Association between post-transplant uric acid level and renal allograft fibrosis: Analysis using Banff pathologic scores from renal biopsies
por: Kim, Deok Gie, et al.
Publicado: (2018)

Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis
por: Jang, Yoonhyuk, et al.
Publicado: (2017)

Pertinent issues in pretransplant recipient workup
por: Modi, Pranjal
Publicado: (2007)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

The Immunomodulating Effects of Thalidomide and Dexamethasone in a Murine Cardiac Allograft Transplantation Model
por: Kim, Soo Jin, et al.
Publicado: (2022)

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
por: Kwon, Hyeok Chan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m974bqo12dvj2m9t3ic5h18buh